Related by context. All words. (Click for frequent words.) 72 refractory ovarian cancer 68 resistant ovarian cancer 66 chemo radiotherapy 66 refractory chronic myeloid 65 platinum refractory 65 taxane chemotherapy 63 relapsed MM 62 relapsed ovarian cancer 62 refractory CML 62 refractory NSCLC 61 de novo kidney transplant 61 heavily pretreated 61 stage chemoresistant ovarian 61 mitoxantrone plus 61 relapsed multiple myeloma 61 doublet chemotherapy 61 depression TRD 60 null responder 60 metastatic malignant 60 chemos 60 nerve toxicity neurotoxicity 60 refractory myeloma 60 superficial bladder cancer 60 leukemia AML 60 Waldenstrom macroglobulinemia 60 Pemetrexed 60 deep venous thromboses 60 cisplatin carboplatin 59 biliary tract cancer 59 hepatitis C genotype 59 rituximab Rituxan 59 Acute myeloid leukemia 59 ulcerative colitis UC 59 refractory metastatic 59 autoantibody positive 59 relapsed CLL 59 allogeneic HSCT 59 relapsing remitting MS RRMS 59 refractory CTCL 59 recurrent ovarian cancer 59 leukemia APL 59 Chronic Myelogenous Leukemia CML 59 Gleevec imatinib 59 basiliximab 59 Viral load 59 cytogenetic responses 59 stage IIIb 59 refractory indolent non 59 acute GvHD 58 cisplatin chemotherapy 58 leukemia ALL 58 gastrointestinal stromal tumor GIST 58 adult chronic ITP 58 Doxil ® 58 rituximab refractory 58 stage IIIB IV 58 gastrointestinal stromal tumors GIST 58 recurrent glioblastoma multiforme 58 metastatic malignant melanoma 58 antiangiogenic therapy 58 recurrent ovarian 58 relapsed Acute Myeloid 58 Paraplatin ® 58 Gleevec resistant 58 relapsed refractory AML 58 interferon beta therapy 58 imatinib Gleevec 58 Myelodysplastic Syndrome 58 refractory epilepsy 58 pancreatic adenocarcinoma 58 visceral metastases 58 metastatic bladder 58 CYT# potent vascular disrupting 58 antiretroviral naïve 58 atypical hemolytic uremic syndrome 58 lenalidomide Revlimid R 58 BARACLUDE ® 57 gemcitabine cisplatin 57 metastatic renal cell carcinoma 57 papillary renal cell carcinoma 57 serous ovarian cancer 57 Fludarabine 57 bladder carcinoma 57 farletuzumab 57 antiretroviral naive 57 chronic granulomatous disease 57 MCyR 57 operable breast cancer 57 PROCRIT ® 57 Toxicities 57 paclitaxel Taxol R 57 tumors GIST 57 refractory AML 57 Myelodysplastic Syndrome MDS 57 pegfilgrastim 57 metaglidasen 57 paclitaxel carboplatin 57 C1 INH deficiency 57 CHOP chemotherapy 57 LHRH receptor positive 57 antiepileptic medications 57 taxane therapy 57 imatinib Gleevec ® 57 decompensated liver disease 57 symptom flare ups 57 hepatorenal syndrome 57 trastuzumab Herceptin ® 57 fistulizing Crohn disease 57 pegylated liposomal doxorubicin 57 Rituxan rituximab 57 recurrent malignant glioma 57 nucleoside naive 57 lymphocytic leukemia 57 FOLFIRI alone 57 cytomegalovirus retinitis 56 underwent liver transplantation 56 Naive Patients 56 pneumocystis carinii pneumonia 56 tinidazole 56 MGd 56 ER CHOP 56 relapsed 56 acute lymphoblastic 56 immune thrombocytopenic purpura ITP 56 dasatinib Sprycel ® 56 etoposide 56 indolent lymphoma 56 Anthracycline 56 Hypotension 56 protease inhibitor PI 56 chronic myeloid 56 ovarian carcinoma 56 cholangiocarcinoma 56 anagrelide 56 Platinol ® cisplatin 56 Valproic acid 56 Amgen Neulasta ® 56 anthracycline taxane 56 idiopathic thrombocytopenic purpura 56 relapsed AML 56 recurrent NSCLC 56 Amgen Neulasta R 56 indolent NHL 56 FUSILEV enhances 56 seminoma 56 TTF Therapy 56 docetaxel chemotherapy 56 clinically evaluable 56 severe hypersensitivity reactions 56 CANCIDAS 56 cytotoxic therapy 56 prednisone prednisolone 56 metastatic kidney 56 opioid dependent 56 sorafenib Nexavar ® 56 Riluzole 56 taxane refractory 56 immunosuppression therapy 56 leukoencephalopathy 56 Ribavirin causes 56 samalizumab 56 Vincristine 56 Tumors shrank 56 refractory cutaneous T 56 basal cell nevus syndrome 56 biochemical relapse 56 refractory DLBCL 56 cilengitide 56 relapsed refractory 56 Hodgkin lymphoma HL 56 nonnucleoside reverse transcriptase inhibitors 56 Vidaza ® 56 refractory HL 56 relapsed leukemia 56 thalidomide Thalomid 56 LHRH analogues 56 Glioblastoma Multiforme GBM 56 Pegylated Interferon 56 Hodgkin lymphoma NHL 56 KRAS mutant tumors 56 advanced medullary thyroid 56 combination antiretroviral therapy 56 TNF alpha antagonist 56 receiving highly emetogenic 56 remitting MS 56 recurrent glioblastoma 56 metastatic GIST 56 demonstrated antitumor activity 56 allogeneic bone marrow 56 anthracyclines taxanes 56 dasatinib Sprycel 56 refractory metastatic colorectal cancer 56 pegylated interferon alpha 56 de novo AML 56 thymic carcinoma 55 gemcitabine Gemzar 55 ZACTIMA 55 non splenectomized 55 cisplatin gemcitabine 55 mycophenolate 55 thrombocytopenic 55 chemotherapy cisplatin 55 Sutent sunitinib 55 Sudhir Agrawal D.Phil 55 Neovascular Age Related Macular 55 weekly intravenous infusions 55 pemphigus 55 refractory ALCL 55 rash urticaria 55 node metastases 55 mutated KRAS 55 adalimumab Humira 55 naïve HCV 55 refractory CLL 55 chlorambucil 55 hematopoietic cancers 55 hematological diseases 55 diabetic kidney 55 Hepatocellular Carcinoma HCC 55 acute leukemias 55 chronic lymphocytic leukemia CLL 55 receiving antiretroviral therapy 55 prostate cancer HRPC 55 primary immunodeficiency PI 55 noninfectious uveitis 55 Herceptin trastuzumab 55 venlafaxine XR 55 FVIII inhibitors 55 HIV HCV coinfected 55 oral clodronate 55 intravenous diuretics 55 induce remission 55 erlotinib Tarceva ® 55 prior chemotherapy regimens 55 gefitinib Iressa 55 nonmelanoma skin cancers 55 ZOLINZA 55 Valcyte tablets 55 receptor tyrosine kinase inhibitor 55 HBeAg positive patients 55 null responder HCV 55 Sanofi Aventis Taxotere 55 Chronic lymphocytic leukemia 55 transarterial 55 chronic GVHD 55 nonsmall cell lung cancer 55 nonmetastatic 55 hA# 55 severe neutropenia 55 urothelial cancer 55 lichen planus 55 APTIVUS r 55 lymphocytosis 55 SJIA 55 receiving VICTRELIS 55 cyclophosphamide chemotherapy 55 trabectedin 55 galiximab 55 maximally tolerated lipid lowering 55 pretransplant 55 adriamycin 55 Decitabine 55 chemotherapeutic regimens 55 potentially hepatotoxic 55 colorectal liver metastases 55 Intravenous immunoglobulin 55 Relapsed Refractory Multiple Myeloma 55 herpes zoster shingles 55 Arranon 55 pulmonary hypertension PH 55 pancreatic NET 55 acute mania 55 Metastatic breast cancer 55 hepatic encephalopathy HE 55 dose escalation phase 55 oral Hycamtin 55 Protease inhibitor 55 serologically active systemic lupus 55 experienced virologic failure 55 AA Amyloidosis 55 IV metastatic melanoma 55 chronic HCV 55 dacarbazine DTIC 55 relapsing multiple sclerosis 55 Glioblastoma multiforme GBM 55 Cremophor 55 Glioblastoma Multiforme 55 LHRH agonists 55 Chronic myeloid leukemia CML 55 Infusion reactions 55 MabThera Rituxan 55 Dasatinib 55 intravenous bisphosphonates 55 IV malignant melanoma 55 aflibercept VEGF Trap 55 prostate carcinoma 55 Gemzar gemcitabine 55 allogeneic hematopoietic stem cell 55 refractory multiple myeloma 55 immune thrombocytopenic purpura 55 Retreatment 55 Relapsed Refractory 55 colorectal cancer liver metastases 55 refractory indolent NHL 55 temozolomide Temodar 55 pemphigus vulgaris 55 recurrent GBM 55 eribulin mesylate 55 Kinoid 55 MGUS 55 symptomatic paroxysmal AF 55 advanced hepatocellular carcinoma 54 squamous cell lung cancer 54 leukemia CLL 54 hematological malignancy 54 Gleevec imatinib mesylate 54 Platinol ® 54 stage IIIb IV 54 ICD shocks 54 nonmetastatic prostate cancer 54 Glivec imatinib 54 KRAS mutations occur 54 systemic antifungal 54 8mg/kg 54 Sezary syndrome 54 HBeAg negative 54 relapsed follicular lymphoma 54 cytoreduction 54 TMP SMX 54 GRNOPC1 contains 54 GnRH agonist 54 remission induction 54 hypereosinophilic syndrome 54 gemcitabine carboplatin 54 previously untreated follicular 54 HSCT 54 eosinophilic asthma 54 systemic anaplastic large 54 cyclophosphamide doxorubicin vincristine 54 imatinib therapy 54 induced anemia 54 neoadjuvant radiation 54 Carcinoid tumors 54 invasive candidiasis 54 HER2 positive cancers 54 Paraplatin ® carboplatin 54 transthyretin amyloidosis 54 EXJADE 54 tumor regressions 54 pouchitis 54 HERCEPTIN 54 chronic HCV infection 54 Mitomycin C 54 bortezomib refractory 54 adjuvant cisplatin 54 lymphoid blast 54 pegylated interferon alfa 54 Castration Resistant Prostate Cancer 54 pancytopenia 54 Bleomycin 54 Tumor shrinkage 54 Cisplatin 54 Alemtuzumab 54 ® lenalidomide 54 alkylating agent 54 relapsed refractory multiple myeloma 54 EGFR mutation positive 54 detectable HCV RNA 54 fluvastatin 54 thrombocytosis 54 autologous transplants 54 vestibular schwannomas 54 neuroendocrine cancers 54 progesterone receptor negative 54 relapsed SCLC 54 histologically confirmed 54 evaluating tivozanib 54 leukemia lymphoma multiple myeloma 54 refractory Hodgkin 54 forodesine 54 achieved CCyR 54 HIV coinfected 54 sorafenib Nexavar 54 CLL SLL 54 cyclophosphamide methotrexate 54 bendamustine 54 hormone refractory 54 clodronate 54 temozolomide 54 peritoneal cancer 54 allogeneic hematopoietic cell 54 heavily pretreated patients 54 achieved ACR# 54 CTAP# 54 smoldering myeloma 54 SCIg 54 Isentress raltegravir 54 efavirenz EFV 54 KRAS wild 54 Sipuleucel T 54 Golimumab 54 Annamycin 54 myeloid metaplasia 54 non hodgkin lymphoma 54 bacillus Calmette Guerin 54 HCV infected 54 irinotecan chemotherapy 54 vinca alkaloid 54 refractory colorectal cancer 54 interferon ribavirin 54 post herpetic neuralgia PHN 54 Enbrel Humira 54 advanced nonsquamous NSCLC 54 Acute Myelogenous Leukemia AML 54 receiving VELCADE 54 Stage IIIB IV 54 metastatic lung cancer 54 immunocompetent 54 malignant pheochromocytoma 54 aldosterone antagonist 54 CellCept mycophenolate mofetil 54 SHPT 54 ritonavir boosted 54 nilotinib Tasigna ® 54 Papillary 54 phenothiazines 54 glomerulonephritis 54 MELAS 54 vincristine doxorubicin 54 HER2 positive metastatic breast 54 indolent follicular non 54 mRCC 54 estramustine 54 TG# [003] 54 alkylating agents 54 metastatic neuroendocrine tumors 54 psoriatic arthritis PsA 54 VELCADE melphalan 54 malignant pleural mesothelioma 54 HBeAg positive 54 invasive fungal infection 54 dirucotide MBP# 54 splenectomized patients 54 EGFR mutant 54 localized renal 54 chemotherapy docetaxel 54 azacitidine 54 castrate resistant 54 histological subtype 54 rALLy 54 PCNSL 54 microwave hyperthermia 54 non metastatic osteosarcoma 54 haematologic 54 type 1diabetes 54 huN# DM1 54 decompensated cirrhosis 54 hematologic toxicity 54 NATRECOR ® 54 cutaneous T 54 bacterial prostatitis 54 concurrent ITP 54 CMV disease 54 immunosuppressed patients 54 myeloablative 54 moderately emetogenic 54 Adjuvant chemotherapy 54 posttransplant 54 tamoxifen Nolvadex ® 54 Non Hodgkins lymphoma 54 Acute Myelogenous Leukemia 54 squamous cell histology 54 endocrine therapies 54 Opportunistic infections 54 myelofibrosis MF 54 gastrointestinal stromal tumors 54 myelogenous leukemia 53 tipranavir ritonavir 53 CD# mAb 53 fallopian tube carcinoma 53 thrombocytopenic patients 53 Synovial sarcoma 53 refractory acute myeloid 53 relapsed acute lymphoblastic 53 inhaled bronchodilators 53 constipation predominant irritable bowel 53 octreotide 53 cyclophosphamide Cytoxan 53 etanercept Enbrel 53 treatment naïve genotype 53 plus prednisone prednisolone 53 panitumumab Vectibix 53 diagnosed glioblastoma multiforme 53 Cytoxan 53 naive HCV 53 idarubicin 53 stage IIIB 53 certolizumab 53 PegIFN RBV 53 tyrosine kinase inhibitors TKIs 53 Diffuse Large B 53 conventional DMARDs 53 rufinamide 53 PTLD 53 denileukin diftitox 53 dyskeratosis congenita 53 Platinol 53 cardiotoxic 53 Epratuzumab 53 antibiotic regimens 53 nevirapine Viramune 53 humanised monoclonal antibody 53 Surgical resection 53 complete cytogenetic response 53 Rheumatoid Arthritis RA 53 HBeAg negative patients 53 papillary carcinoma 53 metastatic sarcoma 53 cidofovir 53 Degarelix 53 candidemia 53 cirrhotic 53 Axitinib 53 treatment naive genotype 53 panobinostat 53 cisplatin resistant 53 uric acid lowering 53 paclitaxel chemotherapy 53 leukemia CML 53 taxane 53 adverse cytogenetics 53 concurrent chemoradiation 53 postoperative chemotherapy 53 non myeloid malignancies 53 non squamous histology 53 lupus nephritis 53 cisplatin 53 conventional chemotherapies 53 TRPV1 agonist 53 commercialize deforolimus 53 rhGH 53 erlotinib Tarceva 53 EFFEXOR XR 53 Cell Lymphoma CTCL 53 acute myeloid 53 Chronic Myeloid Leukemia 53 GISTs 53 recurrent colorectal cancer 53 paricalcitol 53 Alkeran 53 sodium stibogluconate 53 metastatic renal cell 53 urothelial bladder cancer 53 Pneumocystis carinii pneumonia 53 alpha interferons 53 Malignant Glioma 53 HQK 53 liposomal doxorubicin 53 paclitaxel Taxol ® 53 MALT lymphoma 53 MDR tuberculosis 53 neuroleptic 53 biologic DMARD 53 flutamide 53 patients receiving myelosuppressive 53 either acutely decompensated 53 pleural mesothelioma 53 OHR/AVR# 53 haematological cancers 53 antiresorptive 53 YONDELIS 53 drug zotarolimus 53 systemic ALCL 53 urethral stricture 53 prescribed benzodiazepine 53 thymoma 53 relapsed ALL 53 recurrent genital herpes 53 follicular lymphoma FL 53 via intradermal injections 53 mutated KRAS gene 53 cinacalcet 53 constipation OIC 53 TKI therapy 53 symptomatic BPH 53 rFVIIa 53 transfusion syndrome 53 visilizumab 53 post transplant lymphoproliferative 53 ribavirin RBV 53 Sapacitabine 53 metastatic squamous cell carcinoma 53 GIST tumors 53 docetaxel Taxotere ® 53 Renal impairment 53 taxane resistant 53 mercaptopurine 53 Cariprazine 53 partial remissions 53 methotrexate therapy 53 Novartis Gleevec 53 HBeAg 53 systemic lupus erythematosus 53 seropositive patients 53 myeloproliferative neoplasms 53 Bacillus Calmette Guerin BCG 53 Zemplar 53 KETEK 53 Inhaled nitric oxide 53 % CI #.#-#.# [007] 53 osteoporotic compression fractures 53 anti angiogenic therapy 53 Parnate 53 Etanercept 53 FOLFIRINOX 53 refractory gout 53 anti leukemic 53 protease inhibitors PIs 53 squamous cell carcinoma SCC 53 dermatofibrosarcoma protuberans 53 basal cell carcinoma BCC 53 immunosuppressive therapies 53 SPRYCEL ® 53 anthracycline therapy 53 TTR amyloidosis 53 4mg/kg 53 peritumoral brain edema 53 Daclizumab 53 nucleoside analogs 53 topotecan 53 plus gemcitabine 53 subependymal giant cell 53 opiate dependency 53 #mg/m# [002] 53 breast carcinoma 53 pegylated interferons 53 metastatic CRC 53 Temsirolimus 53 pancreatic carcinoma 53 abacavir Ziagen 53 IV melanoma 53 Trastuzumab 53 MAGE A3 ASCI 53 Pegasys peginterferon alfa 2a 53 Helicobacter pylori eradication 53 CR nPR 53 TACE 53 metastatic colorectal carcinoma 53 Carboplatin 53 Wilms tumors 53 chemotherapy regimens 53 Amrubicin 53 Pamidronate 53 schizophrenia CIAS 53 idiopathic pulmonary fibrosis IPF 53 kidney urologic 53 decitabine 53 alefacept 53 Navelbine ® 53 non resectable 53 NATRECOR R 53 nodal metastasis 53 Chronic pancreatitis 53 receiving XGEVA 53 PREZISTA r 53 pediatric Crohn disease 53 pediatric acute lymphoblastic 53 ADPKD 53 Wegener granulomatosis 53 pegylated interferon alpha 2a 53 chemoradiotherapy 53 undetectable viral loads 53 stem cell engraftment 53 lymphoma CTCL 53 hepatoma 53 Atypical antipsychotics 53 chronic HBV 53 HCV antibody 53 anemia neutropenia 53 paroxysmal AF 53 metastatic colorectal 53 cell lymphoma CTCL 53 IV NSCLC 53 chronic eosinophilic leukemia 53 systemic lupus erythematosus SLE 53 CMV infection 53 biologic therapy 53 HER2 overexpression 53 INSPIRE Trial Phase III 53 oblimersen 53 mycophenolate mofetil 53 Anaplastic 53 dacarbazine 53 dexamethasone Decadron 53 APTIVUS R 53 CIMZIA TM certolizumab pegol 53 nephrotoxic drugs 53 Mg Uk 53 interferon alfa 53 Cutaneous T 53 antiestrogen therapy 53 malignant lymphomas 52 CCR5 tropic HIV 52 unresectable tumors 52 induced neuropathy 52 vinorelbine 52 Acute Myeloid Leukaemia AML 52 dyskinetic 52 surgical debulking 52 indwelling catheters 52 peginterferon ribavirin 52 acetonide FA 52 romiplostim 52 Plaquenil 52 neuroblastomas 52 relapsed GBM 52 basal cell skin 52 Stage IIB 52 vincristine 52 hemodynamically stable 52 EOquin TM phase 52 mycosis fungoides 52 Hurler syndrome 52 Idiopathic Pulmonary Fibrosis 52 Previously Untreated 52 alfa 2a 52 dapsone 52 bevacizumab Avastin ® 52 peginterferon alpha 2a 52 immunosuppressant drug 52 uterine fibroid 52 transplantation HCT 52 squamous histology 52 haematologic malignancies 52 Clot busting 52 ErbB2 positive 52 verteporfin 52 alkylating 52 Tyrosine Kinase Inhibitors 52 Enbrel rheumatoid arthritis 52 gastrointestinal stromal tumors GISTs 52 cutaneous melanoma 52 nasopharyngeal carcinoma 52 Nilotinib 52 advanced carcinoid 52 advanced NSCLC 52 pomalidomide 52 neutrophil counts 52 PAH afflicts approximately 52 cytotoxic chemotherapy 52 FOLFOX6 52 Oxaliplatin 52 Rate ORR 52 using lactulose concomitantly 52 HeFH 52 differentiated thyroid 52 stem cell transplantations 52 chronic immune thrombocytopenic 52 metastatic RCC 52 BARACLUDE R 52 Hydroxyurea 52 nasopharyngeal cancer 52 viremic 52 metastatic carcinoid 52 Acute myelogenous leukemia 52 CCyR 52 IMiDs R 52 Fludara 52 macroglobulinemia 52 Cytarabine 52 acute myelogenous leukemia AML 52 relapsed mantle 52 Moxifloxacin 52 nicardipine 52 hypomethylating agents 52 KAPVAY ™ 52 nucleoside analogue 52 abacavir lamivudine 52 refractory prostate cancer 52 huC# DM4 52 suboptimal adherence 52 letrozole Femara 52 renal carcinoma 52 progressive PsA 52 amrubicin 52 acute gout flares 52 VTE prophylaxis 52 BCG refractory 52 pCR 52 nilotinib 52 epithelial tumors 52 cetuximab Erbitux ® 52 GBM tumors 52 eflornithine 52 metastatic renal 52 Severe Primary IGFD 52 medullary thyroid cancer 52 CRp 52 postoperative atrial fibrillation 52 sunitinib malate 52 Idiopathic Pulmonary Fibrosis IPF 52 carcinoid 52 calcineurin inhibitor 52 blastic phase 52 malignant brain 52 HNSCC 52 uterine tumors 52 hepatitis C HCV 52 WNV encephalitis 52 Maribavir 52 Major Depressive Disorder MDD 52 HBeAg seroconversion 52 essential thrombocythemia ET 52 Leukemia AML 52 nucleoside analog 52 overt nephropathy 52 undetectable viral 52 pamidronate 52 fulvestrant 52 multiple myeloma MM 52 Paxil paroxetine 52 pegylated interferon alfa 2a 52 psoriasis vulgaris 52 myeloid leukemia 52 patientswith 52 raloxifene Evista 52 chronic ITP patients 52 immune reconstitution syndrome 52 complement inhibitor eculizumab 52 renal transplants 52 taxotere 52 Staphylococcus aureus infections 52 myeloproliferative disorder 52 malignant ascites 52 systemic corticosteroid 52 pT3 52 dermatologic reactions 52 bacteriuria 52 Femara letrozole 52 5 Fluorouracil 52 steroid refractory GvHD 52 Teriflunomide 52 comorbid ADHD 52 NOMID 52 ORENCIA ® 52 chemotherapeutic drug 52 Vidaza azacitidine 52 AKT inhibitor 52 paclitaxel Taxol 52 torsade de pointes 52 antimetabolite 52 doxorubicin cyclophosphamide 52 durable remissions 52 mCRC acneform rash 52 lymphoblastic leukemia 52 leukaemias 52 immunomodulatory therapy 52 brain tumor glioblastoma multiforme 52 haematological malignancies 52 chlamydial infection 52 chemotherapy regimen 52 immunosuppressant 52 Myelofibrosis 52 genotype 1a 52 CAELYX 52 atypical hyperplasia 52 group metals pgms 52 Immune reconstitution syndrome 52 5FU 52 diabetic retinopathy DR 52 clomipramine 52 Cholangiocarcinoma 52 #I TM# 52 ZYVOX 52 acne vulgaris 52 Host Disease GvHD 52 neurocognitive impairment 52 Diabetic Macular Edema DME 52 autoimmune hemolytic anemia 52 Fluorouracil 52 Leukemia lymphoma 52 irinotecan doxorubicin oxaliplatin paclitaxel 52 JMML 52 vismodegib 52 carcinoid tumors 52 severely immunocompromised 52 CCR5 inhibitor 52 PKC# 52 fulminant 52 proliferative retinopathy 52 fungoides 52 chronic idiopathic 52 novel VDA molecule 52 Flu Cy 52 tricyclic antidepressant 52 unipolar depression 52 TEMODAL 52 OvaRex ® MAb 52 Doxorubicin 52 lysosomal storage disease 52 idiopathic PAH 52 KRN# 52 dalteparin 52 Ophena TM 52 elvucitabine 52 immune modulating 52 colony stimulating factors 52 superficial basal cell carcinoma 52 β blockers 52 overexpress HER2 52 thromboembolic disease 52 CIMZIA ™ 52 gastrointestinal stromal tumor 52 pegylated alpha interferon 52 Eliezer Zomer Ph.D. 52 recurrent glioma 52 polycythemia vera essential thrombocythemia 52 daunorubicin 52 sarcomatoid 52 R sorafenib tablets 52 paclitaxel cisplatin 52 Tarceva erlotinib 52 DOXIL ® 52 pneumocystis pneumonia 52 nonadherent 52 IOP lowering 52 Eltrombopag 52 anticancer therapy 52 Rectal cancer 52 parenteral iron 52 BRCA mutation carriers 52 oxypurinol 52 systemic fungal infections 52 argatroban 52 acute decompensation 52 interferon alfa 2b 52 carcinoma mCRC 52 Natalizumab 52 alcoholic hepatitis 52 Neovascular AMD 52 acute HAE attacks 52 FOSRENOL ® 52 corticosteroid dexamethasone 52 Myelodysplastic syndromes MDS 52 Follicular Lymphoma 52 Progressive Multifocal Leukoencephalopathy 52 thyroid carcinoma 52 sustained virological response 52 #mg ATC 52 ACTEMRA TM 52 underwent surgical resection 52 Kit CD# positive 52 atypical ductal hyperplasia 52 evaluating Xcytrin 52 proton MR spectroscopy 52 interferon therapy 52 chemo resistant 52 toenail onychomycosis 52 deletion 5q 52 Erlotinib 52 selective modulator 52 cytarabine daunorubicin 52 SSRI antidepressant 52 eribulin 52 Leukemias 52 ceftriaxone 52 Pharmacokinetics PK 52 Noxafil 52 azathioprine 52 epoetin beta 52 Hypertensive adverse reactions 52 Carcinoid Syndrome 52 refractory follicular lymphoma 52 nonalcoholic steatohepatitis NASH 52 Fibromyalgia Syndrome FMS 52 Crizotinib 52 Aflibercept 51 splenectomized 51 CML CP 51 Thalomid ® 51 basal cell cancers 51 Philadelphia Chromosome Positive 51 acute STEMI 51 serotonin reuptake inhibitor 51 Eculizumab 51 Nesiritide 51 GvHD 51 anti androgen 51 pregabalin Lyrica 51 Hycamtin 51 maximal doses 51 AVONEX ® 51 ciclosporin 51 alemtuzumab treated 51 immune modulator 51 imatinib resistant 51 hematological disorders 51 transaminase elevations 51 peritoneal carcinomatosis